Recent Comments

Comment RSS

Hypoglycemia News and Research RSS Feed - Hypoglycemia News and Research

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.

Personal CGM improves glucose control for diabetes patients

16. November 2009 04:51
In acknowledgement of this year’s World Diabetes Day, which calls on all those responsible for diabetes care to understand diabetes and take control, Medtronic, Inc. (NYSE: MDT) highlights the growing body of clinical evidence for Personal Continuous Glucose Monitoring (CGM) in improving glucose control for diabetes patients. [More]

Posted in: Device / Technology News | Medical Condition News

Tags: , , , ,

Permalink | Comments (0)

Columbia University Medical Center presents the 2009 Naomi Berrie Awards

16. November 2009 02:29
Columbia University Medical Center will present the 2009 Naomi Berrie Awards to a nationally recognized diabetes researcher, and a promising young investigator, for their outstanding achievements in diabetes research. [More]

Posted in: Medical Condition News

Tags: , , , , , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

On-line journal Diabetic Hypoglycemia calls for greater understanding and taking control of diabetes

12. November 2009 04:36
The on-line journal Diabetic Hypoglycemia (http://www.hypodiab.com/) supports the message of World Diabetes Day 2009 (http://www.worlddiabetesday.org) in their call for greater understanding and taking control of diabetes. [More]

Posted in: Medical Condition News

Tags: , , , ,

Permalink | Comments (0)

Halozyme Therapeutics announces results of its insulin variability study

7. November 2009 00:36
Halozyme Therapeutics, Inc. today announced insulin variability study results that demonstrated reduced intrasubject absorption variability for the combination of lispro, a meal time analog insulin, plus PH20 (hyaluronidase) compared to subcutaneous injection of lispro alone. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , ,

Permalink | Comments (0)

CPEX Pharmaceuticals to feature Nasulin at the Diabetes Technology Meeting

6. November 2009 03:16
CPEX Pharmaceuticals, Inc. today announced that its intranasal insulin product candidate, NasulinTM, will be featured in an oral presentation and four abstracts at the Ninth Annual Diabetes Technology Meeting, November 5-7, 2009 at the Hyatt Regency Airport in San Francisco, California. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , ,

Permalink | Comments (0)

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

3. November 2009 03:07
Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

FDA approves an expanded indication for BYETTA injection

31. October 2009 00:31
Amylin Pharmaceuticals, Inc., and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Medtronic announces ONSET trial results of sensor-enhanced CSII in children

23. October 2009 01:22
Medtronic, Inc. today announced study results from an oral presentation at the International Diabetes Federation’s World Diabetes Congress held in Montreal, Canada. This scientific convention highlights the latest developments in clinical research aimed at improving diabetes management and outcomes. [More]

Posted in: Child Health News | Device / Technology News

Tags: , , , , , ,

Permalink | Comments (0)

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

22. October 2009 07:23
Halozyme Therapeutics, Inc. today announced dose response study results that demonstrated faster insulin absorption and increased peak insulin concentrations after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with regular human insulin and with insulin lispro. The enhanced absorption effects were observed at clinically relevant insulin doses across a broad range of PH20 concentrations. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , ,

Permalink | Comments (0)

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

22. October 2009 00:57
Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , ,

Permalink | Comments (0)

New diabetes algorithm released by AACE for the management of type 2 diabetes

22. October 2009 00:19
A new, first-of-its-kind diabetes algorithm created to help achieve glycemic (blood sugar) control in type 2 patients was published online today in the September/October edition of Endocrine Practice. [More]

Posted in: Medical Condition News

Tags: , , , , , , , , , , ,

Permalink | Comments (0)

New results from ADVANCE provide important insights to reduce diabetes complications

21. October 2009 06:39
New results from ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial ever performed in patients with type 2 diabetes worldwide, provide important insights into the therapeutic strategy to adopt for efficient and safe blood glucose control aimed at the reduction of severe diabetes complications. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , ,

Permalink | Comments (0)

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

21. October 2009 01:07
A meta-analysis of clinical data published today in Diabetologia, the medical journal for the European Association for the Study of Diabetes (EASD), demonstrated that the Novo Nordisk long-acting insulin Levemir® (insulin detemir [rDNA origin] injection) was not associated with any increase in the incidence of cancer when compared to human insulin. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , ,

Permalink | Comments (0)

Health Canada approves new Lantus ClikSTAR reusable insulin pen

20. October 2009 01:12
Health Canada has approved the ClikSTAR reusable insulin pen for use with Lantus, giving patients with diabetes an additional option to safely and effectively achieve and sustain control of their blood sugar levels. The new insulin delivery device was launched today in conjunction with the 20th World Diabetes Congress being held in Montreal, Quebec, making Canada one of the first countries worldwide to launch this state-of-the-art pen. [More]

Posted in: Device / Technology News | Medical Condition News

Tags: , , , , , , , , , ,

Permalink | Comments (0)

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

13. October 2009 06:41
Merck Frosst Canada Ltd. announced today that its new diabetes treatment, JANUMET(TM) (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.